BM
BioMarin Pharmaceutical
BMRN · NASDAQ
$65.51 +1.74% (+$1.12)
1M -6.73%
Market Cap $12.8B
P/E Ratio 175.96x
Div. Yield -
ROE 1.18%
Bulios Fair Price
$66.4
1.4% upside
Current Price
$65.51
Undervalued Fair Value Overvalued
According to Bulios Fair Price, BMRN is currently trading close to its fair value. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
4/9Valuation
36 /100
Fair P/E 175.96x
EV/EBITDA 41.92x
P/S 3.77x
Growth
94 /100
Growing EPS growth 33.89%
Rev. growth 15.40%
FCF growth 136.30%
Profitability
64 /100
Moderate Gross margin 75.55%
Net margin 2.14%
Op. margin 8.02%
Quality
7 /100
Poor ROIC 1.25%
ROE 1.18%
ROA 0.62%
Debt
43 /100
Moderate Debt/Equity 0.66x
Current ratio 2.39x
Int. coverage 2.78x
Stability
42 /100
Moderate Beta 0.23x
Rev. volatility 2.55%
EPS volatility 89.43%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about BMRN
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Alexander Hardy
Employees
3,221
Headquarters
San Rafael
Upcoming events
26 OCT
Earnings
Upcoming earnings report